Media Releases
AtriCure Receives Expanded CE-Mark Indication for AtriClip® Devices for the Reduction of Stroke in Patients with Atrial Fibrillation
August 22, 2024
Expanded indication based on an abundance of clinical evidence for AtriClip Devices MASON, Ohio --(BUSINESS WIRE)--Aug. 22, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and...
AtriCure Receives Regulatory Approval to Sell AtriClip® Devices in China
July 23, 2024
MASON, Ohio --(BUSINESS WIRE)--Jul. 23, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory...
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management
April 18, 2024
MASON, Ohio --(BUSINESS WIRE)--Apr. 18, 2024-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE ®...
AtriCure Announces the First Patient Treated in the LeAAPS™ Clinical Trial
January 31, 2023
Trial will evaluate the safety and effectiveness of the AtriCure AtriClip ® Left Atrial Appendage Exclusion System for stroke prevention in cardiac surgery patients MASON, Ohio --(BUSINESS WIRE)--Jan. 31, 2023-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and...
AtriCure Wins 2022 NACD Diversity, Equity, & Inclusion Award
December 08, 2022
Recognizes Exemplary Board Practices Related to DE&I MASON, Ohio --(BUSINESS WIRE)--Dec. 8, 2022-- AtriCure Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,...
AtriCure Announces Investor Education Webcast with Hybrid AF Therapy Key Opinion Leaders
September 06, 2022
MASON, Ohio --(BUSINESS WIRE)--Sep. 6, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will host an investor education...
AtriCure Announces the First Patient Treated in the HEAL-IST Clinical Trial
June 07, 2022
Trial will evaluate the safety and effectiveness of AtriCure’s Isolator® Synergy ™ Clamp in conjunction with endocardial catheter ablation for the treatment of Inappropriate Sinus Tachycardia MASON, Ohio --(BUSINESS WIRE)--Jun. 7, 2022-- AtriCure, Inc....
AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer
June 01, 2022
MASON, Ohio --(BUSINESS WIRE)--Jun. 1, 2022-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, announced the appointment of Deborah Yount as Chief...
AtriCure Launches EnCompass® Clamp, a part of Isolator Synergy™ Ablation System
April 12, 2022
New clamp is designed to improve efficiency of concomitant ablation procedures MASON, Ohio --(BUSINESS WIRE)--Apr. 12, 2022-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and...
AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients
April 29, 2021
FDA approval results in the only label of its kind for more than 3 million patients in the United States , significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for...